Munich-based antibody-drug conjugate (ADC) specialist Tubulis has completed a sizeable Series B2 financing that shows sustained investor appetite for the ADC category, par
Bristol-Myers Squibb has formed another alliance focusing on antibody-drug conjugates (ADCs) for solid tumours, paying German biotech Tubulis $22.75 million upfront to get
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl